Linosept

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

83 API Suppliers, 29 USDMF, 6 JDMF, 13 EU WC, 4 KDMF, 19 NDC API, 53 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

19 Drugs in Development

19 Drugs in Development

INTERMEDIATES

21 Intermediate Suppliers

21 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

234 FDF Dossiers, 36 FDA Orange Book, 105 Europe, 7 Canada, 25 South Africa, 61 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 600MG, SOLUTION;INTRAVENOUS - 200MG/100ML (2MG/ML), SOLUTION;INTRAVENOUS - 400MG/200ML (2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - 600MG/300ML (2MG/ML)

RELATED EXCIPIENT COMPANIES

1 Minakem, 4 Rochem International Inc, 18 SPI Pharma, 9 DKSH, 1 Pharm-RX Chemical, 9 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 2 Pfanstiehl, 5 Kirsch Pharma, 1 ACG Worldwide, 9 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 30 BASF, 2 CD Formulation, 2 Clariant, 12 Corel Pharma Chem, 6 DFE Pharma, 1 Doshion Polyscience, 1 Esteem Industries, 1 Finar, 8 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 4 Ideal Cures, 5 Ingredion Pharma Solutions, 20 Kerry, 4 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 19 Microlex e.U, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 5 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 25 Roquette, 7 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

83 Fillers, Diluents & Binders, 49 Disintegrants & Superdisintegrants, 48 Coating Systems & Additives, 41 Direct Compression, 41 Thickeners and Stabilizers, 37 Granulation, 29 Controlled & Modified Release, 28 Taste Masking, 22 Chewable & Orodispersible Aids, 22 Lubricants & Glidants, 20 Solubilizers, 19 Parenteral, 17 Film Formers & Plasticizers, 14 Topical, 13 Co-Processed Excipients, 13 Rheology Modifiers, 5 Empty Capsules, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Coloring Agents, 4 Emulsifying Agents, 2 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 44 News #PharmaBuzz

GLOBAL SALES INFORMATION

21 US Medicaid Prescriptions, 32 Regulatory FDF Prices, 8 Annual Reports

MARKET PLACE

47 APIs, 20 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

4 Health Canada Patents

REF. STANDARDS & IMPURITIES

21 Others

21 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 21131 / DOSAGE - SOLUTION;INTRAVENOUS - 200MG/100ML (2MG/ML)

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
LINEZOLID(UNII: ISQ9I6J12J) (LINEZOLID - UNII:ISQ9I6J12J)	LINEZOLID	600mg in 300

Inactive Ingredients

Ingredient Name	Fresenius Kabi Norge As	Mylan Institutional LLC
CITRIC ACID MONOHYDRATE(2968PHW8QP)
DEXTROSE, UNSPECIFIED FORM(IY9XDZ35W2)
SODIUM CITRATE, UNSPECIFIED FORM(1Q73Q2JULR)

Drug Product Composition: Linosept

Linosept

Linosept

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

83 API Suppliers

29 USDMF

6 JDMF

13 EU WC

4 KDMF

19 NDC API

53 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

19 Drugs in Development

INTERMEDIATES

21 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

234 FDF Dossiers

36 FDA Orange Book

105 Europe

7 Canada

25 South Africa

61 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 600MG

SOLUTION;INTRAVENOUS - 200MG/100ML (2MG/ML)

SOLUTION;INTRAVENOUS - 400MG/200ML (2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - 600MG/300ML (2MG/ML)

RELATED EXCIPIENT COMPANIES

1 Minakem

4 Rochem International Inc

18 SPI Pharma

9 DKSH

1 Pharm-RX Chemical

9 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

2 Pfanstiehl

5 Kirsch Pharma

1 ACG Worldwide

9 Actylis

1 Aeon Procare

2 Alcedo Pharmachem

10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

30 BASF

2 CD Formulation

2 Clariant

12 Corel Pharma Chem

6 DFE Pharma

1 Doshion Polyscience

1 Esteem Industries

1 Finar

8 Gangwal Chemicals

1 Huzhou Sunflower Pharmaceutical

4 Ideal Cures

5 Ingredion Pharma Solutions

20 Kerry

4 Keval Exports

5 Kima Chemical

6 Lonza Capsugel

19 Microlex e.U

3 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

4 Novo Excipients

5 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

25 Roquette

7 Seppic

7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

TABLET;ORAL - 400MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INTRAVENOUS - 400MG/200ML (2MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons